Chelsea Therapeutics International Ltd. (CHTP)
-NasdaqCM 1.89 
0.01(0.53%) 12:52PM EDT - Nasdaq Real Time Price
| Prev Close: | 1.88 |
|---|
| Open: | 1.90 |
|---|
| Bid: | 1.89 x 4400 |
|---|
| Ask: | 1.90 x 35600 |
|---|
| 1y Target Est: | 4.63 |
|---|
| Beta: | 1.4 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 1.87 - 1.90 |
|---|
| 52wk Range: | 0.70 - 2.17 |
|---|
| Volume: | 165,346 |
|---|
| Avg Vol (3m): | 1,629,100 |
|---|
| Market Cap: | 126.79M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.30 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- CHELSEA THERAPEUTICS INTERNATIONAL, LTD. FinancialsEDGAR Online Financials(Tue, May 7)
- Chelsea Therapeutics Reports First Quarter 2013 Financial ResultsGlobeNewswire(Wed, May 1)
- CHELSEA THERAPEUTICS INTERNATIONAL, LTD. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 1)
- Chelsea Therapeutics to Present at the 12th Annual Needham Healthcare ConferenceGlobeNewswire(Wed, Apr 24)
- Lead Counsel in Securities Class Action Against Chelsea Therapeutics International Ltd. Announces Court HearingPR Newswire(Fri, Apr 19)
- CHELSEA THERAPEUTICS INTERNATIONAL, LTD. Files SEC form 8-K, Change in Directors or Principal Officers, Financial StaEDGAR Online(Fri, Apr 19)
- Is Chelsea Therapeutics A Buy After Skyrocketing Up Over 150%?at Seeking Alpha(Mon, Apr 8)
- Why Starbucks is a Screaming Buy and 3 Other Hot Stocksat Wall St. Cheat Sheet(Wed, Mar 27)
- Chelsea Therapeutics: A Shoe-In For FDA Approval, Shares Could Double From Hereat Seeking Alpha(Tue, Mar 26)
- 4 Stocks Under $10 Making Big Movesat TheStreet(Thu, Mar 21)
- Chelsea Therapeutics Announces Presentation of Northera(TM) (droxidopa) Study 306 Data at the American Academy of Neurology Annual MeetingGlobeNewswire(Tue, Mar 19)
- Avoid This Biotech Stockat Motley Fool(Fri, Mar 15)
- CHELSEA THERAPEUTICS INTERNATIONAL, LTD. Files SEC form 10-K/A, Annual ReportEDGAR Online(Thu, Mar 14)
- Chelsea Therapeutics to Present at the 25th Annual ROTH ConferenceGlobeNewswire(Tue, Mar 12)
- New Star Analyst Rankings for Chelsea Therapeutics InternatioStarMine(Sat, Mar 9)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.29 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.06 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products.
View More